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Abstract The pyruvate dehydrogenase complex catalyzes the
conversion of pyruvate to acetyl-CoA. The first component (E1)
converts pyruvate to bound acetaldehyde using thiamine diphos-
phate (ThDP) and Mg2+ as cofactors. There is no 3D structure
of E1 available but those of other ThDP-dependent enzymes
show some similarities including a glutamate residue that assists
in ThDP activation. Eukaryotic E1 has an K2L2 structure and
the conserved Glu89 of the L-subunit was identified as a possible
catalytic residue by sequence alignment. Human E1 was
expressed in Escherichia coli and purified. Mutating Glu89 to
glutamine, aspartate and alanine markedly reduces catalytic
activity and the affinity for ThDP, consistent with a role as the
catalytic glutamate.
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1. Introduction
The pyruvate dehydrogenase complex plays a central role in
the process and regulation of glucose metabolism in both
prokaryotes and eukaryotes. It catalyzes the irreversible oxi-
dative decarboxylation of pyruvate and synthesis of acetyl-
CoA:
pyruvateHS-CoANAD!
CH3CO-S-CoAH  CO2
The core structure of the complex contains multiple copies
of three enzymes [1,2] : E1 (pyruvate dehydrogenase, EC
1.2.4.1), E2 (dihydrolipoyl transferase, EC 2.3.1.12) and E3
(dihydrolipoyl dehydrogenase, EC 1.8.1.4). E1 catalyzes the
¢rst and the rate-limiting step [3] of the overall reaction, de-
carboxylation of pyruvate and the oxidative transfer of an
acetyl group to the lipoyl moiety of E2, using thiamine di-
phosphate (ThDP) and magnesium ion as cofactors. In eukar-
yotes and Gram-positive bacteria, E1 is a heterotetramer of
two K- and two L-subunits. The activity of E1 is regulated by
phosphorylation (inactivation catalyzed by pyruvate dehydro-
genase kinase, EC 2.7.1.99) and dephosphorylation (activation
catalyzed by pyruvate dehydrogenase phosphatase, EC
3.1.3.43) of the K-subunit. The ratio of the active to the in-
active forms of E1 is regulated by both nutritional status and
hormones (for review see [4]). Mutations in the K-gene of E1
are responsible for severe defects of glucose metabolism with
syndromes such as fatal neonatal lactic acidosis, psychomotor
retardation with or without neurodegeneration and a male-
only syndrome of ataxia, mild mental retardation and carbo-
hydrate sensitivity (for review see [5]). Many chemical mod-
i¢cation studies of E1 have been performed. Cysteine [6^8],
histidine [7], tryptophan [9,10], arginine [11,12] and lysine [13]
residues have been suggested to be located in or near the
active site, but the role of these residues in the mechanism
of E1 is far from clear.
Since the pioneering work of Breslow [14], it has been gen-
erally accepted that ThDP-dependent enzymes apply the same
chemical mechanism to catalyze a wide range of reactions.
The dipolar carbanion (or ylid) is the active form of the
coenzyme, and the negatively charged C2 initiates a nucleo-
philic attack on the carbonyl carbon of the substrate. The
determination of the X-ray structures of transketolase [15],
pyruvate oxidase [16,17], pyruvate decarboxylase [18,19] and
benzoylformate decarboxylase [20] has clari¢ed the mecha-
nism of enzymatic catalysis. These crystal structures reveal
some common features that are necessary for the binding
and activation of ThDP. In each case, the ThDP-binding
site is located in a deep cleft at an interface between subunits,
such that residues from both subunits interact with the cofac-
tor and are required for binding. The ThDP-binding motif
identi¢ed by Hawkins et al. [21] and subsequently found in
all known ThDP-dependent enzymes [22] is responsible for the
binding of a metal ion that anchors ThDP through its phos-
phate groups. This motif is located in the C-terminal domains
of pyruvate oxidase, pyruvate decarboxylase and benzoylfor-
mate decarboxylase but is in the N-terminal domain of trans-
ketolase. ThDP is bound in the ‘V’ conformation that brings
the 4P-amino group of the pyrimidine ring very close to the
reactive C2 atom of the thiazolium ring. In each case, there is
a conserved glutamate residue that interacts with N1P of the
aminopyrimidine ring and is thought to be involved in the
formation of the imino group at the 4P position which in
turn promotes the formation of the active ylid [15,23]. Sub-
stitution of this glutamate residue in various ThDP-dependent
enzymes results in a substantial decrease of enzyme activity
[24^26]. Because of the very poor homology shared among
ThDP-dependent enzymes, the identi¢cation of the active
site amino acid residues in E1 has proved to be di⁄cult by
protein sequence alignment.
In this paper, we suggest that Glu89 of the L-subunit is the
catalytic glutamate of human pyruvate dehydrogenase, based
on the results of protein sequence alignment with transketo-
lase (EC 2.2.1.1), and between the E1L subunits of pyruvate
dehydrogenase complex and related enzymes from various
species. This hypothesis is strongly supported by the results
of substitution of Glu89 with glutamine, aspartate and alanine.
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2. Materials and methods
2.1. Materials
Chemicals used were of the highest quality available commercially.
T4 DNA polymerase, T4 DNA ligase, and restriction enzymes were
from Progen (Brisbane, Australia). Sequencing and mutagenesis DNA
oligonucleotides were purchased from Paci¢c Oligos (Lismore, Aus-
tralia). DNA sequencing was performed using the Big Dye Termina-
tor kit from Perkin-Elmer (Norwalk, CT, USA).
2.2. Sequences and sequence alignment
Sequences were obtained from the GenBank or SwissProt databases
and aligned using ClustalW [27]. Residues are numbered from the
initiating methionine and include the mitochondrial transit peptides
of each E1 subunit.
2.3. Plasmids and Escherichia coli strains
The plasmid pQE-9-6HE1K/E1L that was used for expression of
PDH in E. coli was kindly provided by Prof. M.S. Patel, Department
of Biochemistry, SUNY, Bu¡alo, NY, USA. It is derived from pQE-9
(Qiagen, Valencia, CA, USA) and encodes the mature form (i.e. mi-
nus the mitochondrial transit peptide) of both the K- and L-subunits
of human E1. The K-subunit has a hexahistidine tag attached to the
N-terminus of the protein that does not a¡ect the function of the
enzyme [28]. Propagation of this plasmid was done in E. coli
JM109, or in E. coli BMH 71-18 mutS during mutagenesis. E. coli
M15 cotransformed with pREP4 (Qiagen) was used for expression.
Transformation and other molecular biological techniques generally
followed the methods described by Sambrook et al. [29].
2.4. Site-directed mutagenesis
Mutagenesis was performed by the ‘unique site elimination’ method
described by Deng and Nickolo¡ [30]. Brie£y, a control primer was
designed to introduce a mutation in a unique restriction site, SmaI or
NdeI. After the vector was denatured by alkali and puri¢ed by sodium
acetate-ethanol precipitation, the control primer and the primer with
the desired mutation were annealed to the same strand of the plasmid.
The mutant strand was synthesized by T4 DNA polymerase and T4
ligase in the presence of dNTP and ATP. The mixture was trans-
formed into E. coli BMH 71-18 mutS and then into E. coli JM109.
Before each transformation, the mixture was digested by SmaI or
NdeI to linearize the parent plasmid. To obtain the desired mutants,
5P-GACACTCCCATATCACATATGGGCTTG-3P was used to
change Glu89 to histidine and introduce a NdeI site to facilitate
screening of mutants. The bases in each primer that di¡er from
wild-type are underlined. 5P-ACTTTCACCCGTGGCCTTTCCGTC-
3P was used as the control primer to introduce a silent mutation at
Arg127 of K-subunit gene and eliminate the unique SmaI site. In the
second round of mutation, 5P-CTGAGAGTGCATGCTATGCGGT-
GTG-3P was used as the control primer to eliminate an NdeI site
outside the L-subunit gene, and the codon of His89 was replaced by
that of glutamine (CAG), aspartate (GAT) or alanine (GCA). Mutant
plasmids were screened by NdeI digestion and the whole length of K-
and L-subunit genes was sequenced.
2.5. Expression and puri¢cation
The plasmid carrying either the wild-type or mutant PDH gene was
transformed into E. coli M15 (pREP4) for expression. The method for
expression and puri¢cation was adapted from that described by Ko-
rotchkina et al. [28]. When the OD600 of the culture reached 0.9^1.0,
the cells were induced with 0.1 mM IPTG and incubated overnight at
25‡C. The enzyme was puri¢ed [28] using 5 ml of HiscBind resin
(Novagen, Madison, WI, USA). The puri¢ed enzyme was precipitated
with 50% saturated ammonium sulfate in the presence of 0.2 mM
DTT and 1 mM EDTA. Finally, it was desalted by gel ¢ltration using
a PD-10 column (Pharmacia-Biotech, Melbourne, Australia) and
stored for several days at 4‡C in 50 mM potassium-phosphate bu¡er
(pH 7.0) containing 0.2 mM DTT and 1 mM EDTA. For long-term
storage at 320‡C, 20% glycerol was added.
2.6. Protein determination
The protein concentration was determined using Coomassie bril-
liant blue G-250 [31]. The OD595 was measured in a 96-well plate
using a SPECTRAmax 250 Microplate Spectrophotometer, with bo-
vine serum albumin as standard.
2.7. Enzyme activity assay
PDH samples were separated from DTT (which interferes in the
assay) by gel ¢ltration on a PD-10 column. The enzyme activity was
determined by measuring the rate of production of hydroxyethyl-
ThDP, which reduces DCPIP and results in a decrease of OD600
[32]. The ¢nal 200 Wl reaction mix contained 2 mM MgCl2, 0.2 mM
ThDP, 0.2 mM pyruvate, 80 WM DCPIP, 50 mM potassium-phos-
phate bu¡er (pH 7.0) and enzyme. The reaction was started by adding
pyruvate and the absorbance at 600 nm was monitored for 5 min
using a SPECTRAmax 250 Microplate Spectrophotometer. To deter-
mine the Km for pyruvate, the concentration of pyruvate was varied
and the rate was measured as described above.
2.8. ThDP binding assay
Cofactor binding to the apoenzyme was determined by £uorescence
quenching. In a cuvette, the apoenzyme was diluted to a ¢nal volume
of 2 ml using 50 mM potassium-phosphate bu¡er (pH 7.0) containing
2 mM MgCl2 and 1 mM DTT. The protein concentration was in the
range 0.2^0.4 mg/ml. The concentration of ThDP was increased by
adding small volumes (usually 2^5 Wl) of a stock solution to the same
cuvette. The sample was then left to stand at room temperature for
5 min to establish equilibrium, then the emission spectrum was re-
corded on a JASCO FP-770 Spectro£uorometer with an excitation
wavelength of 300 nm (bandwidth 5 nm) and an emission wavelength
over the range of 300^400 nm (bandwidth 5 nm). The excitation wave-
length of 300 nm was chosen to minimize light absorption by ThDP.
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Fig. 1. Alignment of human transketolase with pyruvate dehydro-
genase and related enzymes. The upper schematic shows an align-
ment between human transketolase (TK) and the K- and L-subunits
of human E1. Dark bars indicate regions of high (s 50%) sequence
conservation, while the stippled regions represent the mitochondrial
transit peptides of E1K and E1L. The positions of the ThDP-bind-
ing motif and the catalytic glutamate are also shown. The lower
part of the diagram shows details of the alignment between human
TK, E. coli DXP synthase (DXPS) and selected E1L subunits from
pyruvate dehydrogenase (PDH), the branched-chain 2-ketoacid de-
hydrogenase (BCDH) and acetoin dehydrogenase (ACDH). The
conserved amino acids are indicated in upper case if totally con-
served in all the E1L sequences shown, and in lower case if con-
served in at least two-thirds of those sequences. Abbreviations for
the species are: Bsu, Bacillus subtilis ; Eco, E. coli ; Hsa, Homo sapi-
ens ; Kpn, Klebsiella pneumoniae; Mge, Mycoplasma genitalium ;
Ppu, Porphyra purpurea ; Psa, Pisum sativum ; Rno, Rattus norvegi-
cus ; Sce, Saccharomyces cerevisiae and Spo, Schizosaccharomyces
pombe.
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3. Results
3.1. Sequence alignment
Due to its distant evolutionary relationship to those ThDP-
dependent enzymes with known crystal structures, together
with its organization into K- and L-subunits, it has been di⁄-
cult to identify the catalytic glutamate residue of the E1 of
any 2-ketoacid dehydrogenase complex. Robinson and Chun
[33] proposed an alignment in which Glu59 of the L-subunit
(Glu89 in our numbering) of human E1 corresponded to the
presumed catalytic glutamate of transketolase. However, our
con¢dence in this identi¢cation was somewhat weakened by
the fact that it failed to locate the catalytic glutamate of yeast
PDC, and that no corresponding glutamate was aligned in
Bacillus stearothermophilus or E. coli E1. More recently,
Sprenger et al. [34] have alluded to an alignment between
transketolases, PDH E1 and DXP synthases, and Dr.
Sprenger has kindly provided an example of this alignment
to us that we have adapted and extended (Fig. 1).
The overall similarity between human E1 and human trans-
ketolase is not high (32%) but contains regions with much
higher similarity. One of these regions is near Glu89 of E1L
which aligns with Glu366, the catalytic glutamate of human
transketolase [35]. Comparison with the E1L subunit of pyr-
uvate dehydrogenase from other species and the E1L of re-
lated enzymes such as the branched-chain 2-ketoacid dehydro-
genase complex and the acetoin dehydrogenase complex
revealed that this glutamate was conserved without exception.
We therefore propose that Glu89 of human E1L is the catalytic
residue and to test this hypothesis we introduced various mu-
tations at this position, expressed the enzymes and measured
some of their catalytic properties.
3.2. Expression and puri¢cation
The design of pQE-9-6HE1K/E1L is such that it may ex-
press more E1L than E1K [28]. We observed that when the
culture was induced at 37‡C, or using a high IPTG concen-
tration (e.g. 0.8 mM), E1L was found mostly in inclusion
bodies and the soluble E1L was insu⁄cient to saturate E1K
(data not shown). When induced at 25‡C using 0.1 mM IPTG,
the soluble fraction of E1L was increased and was able to
saturate E1K, as judged by the observation that the two bands
corresponding to the 41 kDa K-subunit and 36 kDa L-subunit
gave similar density in SDS-PAGE of the puri¢ed E1 (data
not shown). Wild-type and mutant enzymes were obtained at
better than 95% purity by the method described. The mutants
were unstable in the absence of DTT.
3.3. Kinetic studies
The speci¢c activity of the wild-type enzyme (31.7 mU/mg,
Table 1) is very similar to that reported (26.9 mU/mg) pre-
viously [28] using the same assay. The catalytic e⁄ciency of
the mutant enzymes is much lower; the speci¢c activity of
E89D was the highest among the mutants but is only about
one-seventh of wild type, while E89Q and E89A had very low
activities of 5% and 1%, respectively (Table 1). The Km for
pyruvate of both wild-type and E89D were determined (Fig. 2
and Table 1) and it was found that the value was elevated by
more than ¢ve-fold for this mutant.
In the process of enzyme puri¢cation, ThDP was not added
and the puri¢ed products were predominantly apoenzyme;
with no added ThDP the activity of wild-type is only about
0.6% of that observed in the presence of a saturating concen-
tration of ThDP. The ThDP saturation curve yielded a Km for
this cofactor of 0.15 þ 0.02 WM. Because of the very low ac-
tivity and poor stability in the absence of DTT of the mu-
tants, further kinetic studies were not pursued. Instead, we
measured ThDP binding more directly as outlined below.
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Fig. 2. Substrate saturation curve of human pyruvate dehydrogenase
E1. A: Wild-type. B: The LE89D mutant.
Table 1
Characteristics of wild type and mutant of human pyruvate dehydrogenase E1
Wild type E89D E89Q E89A
Speci¢c activity (mU/mg) 31.7 4.4 1.6 0.32
Km for pyruvate (WM) 5.3 þ 0.6 29 þ 5 N.D. N.D.
Ks for ThDP (WM) 0.72 þ 0.05 198 þ 37 37 þ 13 414 þ 63
N.D., not determined.
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3.4. ThDP binding
The binding of ThDP can be followed by its e¡ect on tryp-
tophan £uorescence. The advantage of this technique is that it
is not necessary to remove DTT which is needed for stability
of the mutants but which interferes in the activity assay. The
£uorescence emission of PDH was excited at 300 nm and
exhibited a maximum at 334 nm (Fig. 3A). As increasing
amounts of ThDP were added to the solution of wild type
enzyme, the £uorescence signal at 334 nm decreased. After
correction for ¢lters e¡ect arising from light absorption by
ThDP, the decrease of £uorescence followed the equation:
vF  aThDP=Ks  ThDP
where vF is the decrease of the £uorescence signal, a is a
£uorescence constant of the protein and Ks is the dissociation
constant of the ThDP-enzyme complex.
This equation gave a good ¢t to the data for wild-type (Fig.
3B) and mutants (data not shown). The value of Ks for mu-
tants determined by this method (Table 1) shows that the
binding of ThDP to E89Q is about 50 times weaker than
wild type. The e¡ects of the aspartate and alanine substitu-
tions are even more pronounced, resulting in 275- and 575-
fold weaker binding, respectively.
4. Discussion
ThDP-dependent enzymes utilize this cofactor to catalyze
reactions involving the cleavage of a carbon-carbon bond ad-
jacent to an oxo function. There are two common intermedi-
ates; the ylid form of ThDP, resulting from the deprotonation
of the C2 atom of the thiazolium ring in the initial step of the
catalytic cycle, and an K-carbanion which is formed after the
nucleophilic attack of the ylid on the substrate (for review see
[36]). In the crystal structures of transketolase, pyruvate oxi-
dase, pyruvate decarboxylase and benzoylformate decarboxy-
lase, there is no enzymatic base in a position suitable for
proton abstraction from the C2 atom of the thiazolium ring
of ThDP. Instead, a cofactor-assisted deprotonation mecha-
nism has been proposed [15,23] where a conserved glutamate
residue, in a position that allows it to form a hydrogen bond
with N1P, catalyzes the conversion of the aminopyrimidine to
its imino tautomeric form. The 4P-imino group, in turn, ac-
cepts a proton from C2, thereby forming the ylid. The partic-
ipation of the 4P-amino group and N1P are supported by the
experiments showing that pyruvate decarboxylase reconsti-
tuted with ThDP analogs missing either of these functional-
ities is catalytically inactive [37,38].
In this paper, we deduced from protein sequence alignment
that Glu89 of the L-subunit is the catalytic glutamate for the
E1 component of human pyruvate dehydrogenase. The results
of replacing Glu89 by mutagenesis suggest that hydrogen
bonding is important for ThDP binding and that the acidic
character of the carboxyl group is critical for catalysis. Thus,
E89Q has the best ThDP-binding ability among mutants,
while E89D has the highest activity, although both are
much lower than wild-type. Small changes of the side chain
cause signi¢cant decrease in ThDP binding (E89Q) and activ-
ity (E89D). Evidently, the E89D mutant enzyme undergoes a
structural perturbation that permits some interaction of the
carboxyl group of aspartate with N1P to enable catalysis at the
cost of a weakened binding of ThDP.
It might have been expected that E89Q and E89A would be
totally inactive. However, a similar e¡ect has been reported
upon mutagenesis of the catalytic glutamate of yeast trans-
ketolase to glutamine or alanine [24] and that of Zymomonas
mobilis pyruvate decarboxylase to glutamine [25]. Conversely,
mutagenesis of the catalytic glutamate of yeast pyruvate de-
carboxylase to glutamine or alanine [26] abolishes almost all
activity. Evidently the e¡ect of mutagenesis of the catalytic
glutamate varies between di¡erent ThDP-dependent enzymes
and in this context it is of interest that Kern et al. [39] have
proposed that the main role of this residue is to increase the
rate, rather than the extent, of C2 deprotonation. Since E1
has an intrinsically low activity compared to other ThDP-
dependent enzymes, it might be expected to be less susceptible
to replacement of the catalytic glutamate.
In conclusion, we have identi¢ed Glu89 of the L-subunit of
the E1 component of human pyruvate dehydrogenase com-
plex as the catalytic glutamate. This is the ¢rst member of
the enzyme family comprising the 2-ketoacid dehydrogenase
complexes where this residue has been identi¢ed. This enzyme
has a remote evolutionary relationship only to the ThDP-de-
pendent enzymes for which 3D structures have been solved so
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Fig. 3. Fluorescence quenching of human pyruvate dehydrogenase
E1 by added ThDP. A: Tryptophan £uorescence was excited at 300
nm and the emission spectrum was measured over a range of added
ThDP concentrations from 0 WM (top curve) to 40 WM (bottom
curve). B: The decrease of £uorescence signal at 334 nm was meas-
ured as a function of the ThDP concentration.
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it will be of great interest if our proposal can be veri¢ed by
structure determination of E1.
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